January's FDA oncology approvals offer new treatment options for breast cancer, mantle cell lymphoma, and other malignancies.

Here is a select list of cancer therapies approved by the FDA throughout the month of January, featuring patient populations ...

The FDA has approved a new treatment for patients with a common form of breast cancer that has spread to other parts of the ...

The U.S. Food and Drug Administration has approved Enhertu (trastuzumab deruxtecan) for the treatment of adult patients with ...

Less than two months after an accelerated approval from the FDA, a drug combination featuring Pfizer’s Braftovi has turned in ...

The drug, suzetrigine, will be sold under the brand name Journavx and is the first new class of pain medicine approved in ...

The FDA is reviewing new vaccines for meningitis and chikungunya and therapies for Parkinson disease and PTSD.

Now, scientists have found promise in permanently eliminating the virus, thanks to a drug already approved by the FDA to fight cancer. Once a death sentence, human immunodeficiency virus (HIV ...

Trastuzumab deruxtecan is approved for HR ... ultralow metastatic breast cancer following endocrine therapy.” Trastuzumab deruxtecan is a HER2-directed antibody-drug conjugate (ADC) developed ...

Roche Holding said the U.S. Food and Drug Administration approved a test to identify patients with a specific type of breast cancer. The Swiss pharmaceutical company said the FDA backed a label ...

The Food and Drug Administration (FDA ... or HER2-ultralow (IHC 0 with membrane staining) breast cancer, as determined by an FDA-approved test, that has progressed on 1 or more endocrine therapies ...

The approval emphasizes the importance of HER2 status testing in metastatic breast cancer to identify eligible patients for Enhertu treatment. The antibody drug conjugate was approved for patients ...